Clovis Oncology Stock News

Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea

Once again, I drew the short (no pun intended) end of the stick and must discuss stocks to sell right now. Understandably a sensitive topic and one that arouses myriad emotions, I'm just going to stic

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | Penn

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus contin

There's nothing like a good old-fashioned bankruptcy warning to make a stock pop on a given day. Today, the latest speculative frenzy appears to be underway with Clovis Oncology (NASDAQ: CLVS ).

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Upgrades According to Stifel, the prior rating for Clearside Biomedical Inc (NASDAQ:CLSD) was changed from Hold to Buy. In the third quarter, Clearside Biomedical showed an EPS of $0.13, compared to $

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 212.8% to close at $12.51 on Wednesday after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimac

U.S. stocks traded lower toward the end of trading , with the Nasdaq Composite dropping 200 points on Wednesday. The Dow traded down 1.44% to 32,684.65 while the NASDAQ fell 1.89% to 10,416.00. The S&

Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares jumped 219% to $12.80 after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimack is eligible for up to $

U.S. stocks traded lower midway through trading as investors focused on the outcome of the midterm elections. The Dow traded down 0.64% to 32,950.16 while the NASDAQ fell 0.76% to 10,535.77. The S&P 5

Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?